Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TKI Cessation in CML Patients with Stable Molecular Response
NCT04626024Phase 2Active, not recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Dec 2020
- Primary completion
- Nov 2028
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial in chronic myeloid leukemia (CML), sponsored by Baylor College of Medicine. Primary endpoint: Molecular Relapse Free Survival at 6 months. Started Dec 2020; status: active, not recruiting.
02
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT04626024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04626024.